Amir P Tamiz

6586405, Jul 1, 2003

Dec 7, 2000

09/733645

Joseph Edward Semple - San Diego CA
Michael I. Weinhouse - Escondido CA
Odile Esther Levy - San Diego CA
Edwin L. Madison - San Diego CA
Amir P. Tamiz - San Diego CA

Corvas International, Inc. - San Diego CA

C07K 506

514 19, 514 18, 530331

Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

6605621, Aug 12, 2003

Jul 30, 2002

10/209170

Alan P. Kozikowski - Princeton NJ
Gian Luca Araldi - San Diego CA
Amir P. Tamiz - Washington DC

Georgetown University - Washington DC

A01N 4340

514320

The invention provides compounds of formula(I): wherein X, L, and X have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinsons disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.

7019019, Mar 28, 2006

Dec 18, 2003

10/740946

David F. Duncan - San Diego CA, US
L. Josue Alfaro-Lopez - San Marcos CA, US
Mallareddy Komandla - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Ofir Moreno - Del Mar CA, US
Joseph E. Semple - San Diego CA, US
Amir P. Tamiz - San Diego CA, US

Dendreon Corporation - Seattle WA

A61K 31/44
A61K 31/425
A61K 31/38
C07D 333/22
C07D 211/72

514352, 514369, 514438, 546312, 548205, 549 77

The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.

7262211, Aug 28, 2007

Dec 4, 2002

10/309781

Amir P. Tamiz - San Diego CA, US
L. Josue Alfaro-Lopez - San Marcos CA, US
Odile Esther Levy - San Diego CA, US
Joseph Edward Semple - San Diego CA, US

Dendreon Corporation - Seattle WA

A61K 31/4412
C07D 211/04

514346, 546223, 546225, 546245

Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

20110275562, Nov 10, 2011

May 6, 2009

12/991658

Sefik Alkan - Baltimore MD, US
Amir Tamiz - Silver Spring MD, US
Kelly Marie Kitchens - Laurel MD, US
Malarvizhi Durai - Ellicott City MD, US
Neil Poloso - Rockville MD, US
Rosa A. Carrasco - Baltimore MD, US

A61K 38/08
C07K 5/09
C07K 5/103
C07K 5/083
C07K 5/097
A61P 3/00
C07K 5/093
A61K 38/06
A61K 38/07
A61P 3/10
A61P 17/00
C07K 7/06
C07K 5/087

514 69, 530328, 530329, 530330, 530331, 514 217, 514 216, 514 218, 514 219, 514 186

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

20120027720, Feb 2, 2012

Jun 24, 2011

13/168734

Amir TAMIZ - Silver Spring MD, US
Sefik Alkan - Baltimore MD, US

A61K 38/08
A61K 38/07
A61P 3/10
A61K 39/385
A61K 39/395
A61K 38/20
A61K 38/18
C07K 17/00
A61P 35/00

424 852, 530330, 530329, 514 219, 514 218, 514 69, 514 193, 5303917, 530322, 530351, 4241781, 514 76, 514 217, 4241931

The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.

20130316950, Nov 28, 2013

Dec 12, 2011

13/992998

Aleksander S. Popel - Lutherville MD, US
Elena V. Rosca - Baltimore MD, US
Jacob E. Koskimaki - Baltimore MD, US
Corban G. Rivera - Baltimore MD, US
Niranjan B. Pandey - White Marsh MD, US
Amir P. Tamiz - Silver Spring MD, US

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

C07K 14/78

514 133, 530300, 530326, 530328, 530327, 514 172, 435375

Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.

6440996, Aug 27, 2002

Oct 7, 1999

09/414106

Alan P. Kozikowski - Princeton NJ
Gian Luca Araldi - San Diego CA
Amir P. Tamiz - Washington DC

Georgetown University - Washington DC

A61K 31445

514316, 514326, 514332, 546186, 546187, 546189, 546191, 546209, 546228, 548131, 549425, 549426

The invention provides compounds of formula (I): wherein X and X are substituted piperidine, cyclohexane, or tetrahydropyran rings, and L is a linking group between X and X ; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinsons disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.